PMID- 21715313
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20210206
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 118
IP  - 9
DP  - 2011 Sep 1
TI  - Reduced-intensity conditioning therapy with busulfan, fludarabine, and 
      antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation 
      in acute leukemia and myelodysplastic syndrome.
PG  - 2609-17
LID - 10.1182/blood-2011-02-339838 [doi]
AB  - Any role for reduced-intensity conditioning (RIC) before hematopoietic cell 
      transplantation (HCT) from a human leukocyte antigen (HLA)-haploidentical donor 
      remains to be defined. We therefore assessed 83 patients (age, 16-70 years): 68 
      with acute leukemia (including 34 in remission and 34 with refractory disease) 
      and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with 
      busulfan, fludarabine, and antithymocyte globulin. The HLA-haploidentical donors, 
      offspring (n = 38), mothers (n = 24), or siblings (n = 21) of patients, underwent 
      leukapheresis after receiving granulocyte colony-stimulating factor, and donated 
      cells were transplanted without further manipulation. Cyclosporine and 
      methotrexate were given for GVHD prophylaxis. The cumulative incidences of 
      neutrophil engraftment, grade 2 to 4 acute GVHD, chronic GVHD, and 
      transplantation-related mortality after HCT, were 92%, 20%, 34%, and 18%, 
      respectively. After a median follow-up time of 26.6 months (range, 16.8-78.8 
      months), the event-free and overall survival rates were 56% and 45%, 
      respectively, for patients with acute leukemia in remission; 9% and 9%, 
      respectively, for patients with refractory acute leukemia; and 53% and 53%, 
      respectively, for patients with myelodysplastic syndrome. HCT from an 
      HLA-haploidentical family member resulted in favorable outcomes when RIC 
      containing antithymocyte globulin was performed. This study is registered at 
      www.clinicaltrials.gov as #NCT00521430 and #NCT00732316.
FAU - Lee, Kyoo-Hyung
AU  - Lee KH
AD  - Hematology Section, Department of Internal Medicine, University ofUlsan, College 
      of Medicine, Asan Medical Center, Seoul, Korea. khlee2@amc.seoul.kr
FAU - Lee, Je-Hwan
AU  - Lee JH
FAU - Lee, Jung-Hee
AU  - Lee JH
FAU - Kim, Dae-Young
AU  - Kim DY
FAU - Seol, Miee
AU  - Seol M
FAU - Lee, Young-Shin
AU  - Lee YS
FAU - Kang, Young-Ah
AU  - Kang YA
FAU - Jeon, Mijin
AU  - Jeon M
FAU - Hwang, Hyun-Ju
AU  - Hwang HJ
FAU - Jung, Ah-Rang
AU  - Jung AR
FAU - Kim, Sung-Han
AU  - Kim SH
FAU - Yun, Sung-Cheol
AU  - Yun SC
FAU - Shin, Ho-Jin
AU  - Shin HJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00521430
SI  - ClinicalTrials.gov/NCT00732316
PT  - Evaluation Study
PT  - Journal Article
DEP - 20110628
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - FA2DM6879K (Vidarabine)
RN  - G1LN9045DK (Busulfan)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antilymphocyte Serum/*administration & dosage
MH  - Busulfan/*administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/prevention & control
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - HLA Antigens/*analysis
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Histocompatibility
MH  - Humans
MH  - Infections
MH  - Kaplan-Meier Estimate
MH  - Leukemia/mortality/*surgery
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/mortality/*surgery
MH  - Peripheral Blood Stem Cell Transplantation/*methods
MH  - Retrospective Studies
MH  - T-Lymphocytes/immunology
MH  - Tissue Donors
MH  - Transplantation Conditioning/*methods
MH  - Treatment Outcome
MH  - Vidarabine/administration & dosage/*analogs & derivatives
MH  - Young Adult
EDAT- 2011/07/01 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/07/01 06:00
PHST- 2011/07/01 06:00 [entrez]
PHST- 2011/07/01 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - S0006-4971(20)40754-2 [pii]
AID - 10.1182/blood-2011-02-339838 [doi]
PST - ppublish
SO  - Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 
      Jun 28.